Cinacalcet hydrochloride Chemical Properties

Melting point:

175-177°C

storage temp. 

Inert atmosphere,2-8°C

solubility 

insoluble in H2O; ≥17.85 mg/mL in DMSO; ≥56 mg/mL in EtOH

form 

solid

color 

White to off-white

InChI

InChI=1/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/s3

InChIKey

QANQWUQOEJZMLL-LSQUZMQTNA-N

SMILES

C12C=CC=CC1=CC=CC=2[C@@H](C)NCCCC1=CC=CC(C(F)(F)F)=C1.Cl |&1:10,r|

CAS DataBase Reference

364782-34-3(CAS DataBase Reference)

Safety Information

Safety Statements 

24/25

HS Code 

29214990

Cinacalcet hydrochloride Usage And Synthesis

Description

Cinacalcet is the first entry in a new class of therapeutic agents called the calcimimetics. It was launched as an oral treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in patients with parathyroid carcinoma. SHPT is associated with increased parathyroid hormone (PTH) secretion, which is triggered by low serum levels of calcium resulting from the failure of the kidney to clear phosphorous from the body and its inability to produce sufficient quantities of vitamin D. The consequences of increased PTH include stimulation of osteoclastic activity, cortical bone resorption and marrow fibrosis. PTH secretion is primarily regulated by the calcium-sensing receptor (CaR), which is located on the surface of the chief cell of the parathyroid gland. Calcimimetics bind to CaR and increase the sensitivity of CaR to extracellular calcium, thereby enabling its activation at subnormal levels of serum calcium. As a result, in the presence of these agents, the low levels of endogenous calcium in patients with renal failure are able to exert a suppressive effect on PTH secretion. Parathyroid carcinoma is also associated with elevated PTH levels, which are driven by autonomous parathyroid gland activity and subsequently lead to hypercalcemia. Although surgical resection is the primary therapy for treating hypercalcemia in parathyroid carcinoma patients, calcimimetics offer a nonsurgical alternative for patients with failed parathyroidectomy, metastatic parathyroid carcinoma, or high surgical risk. The recommended dosage of cinacalcet for the treatment of SHPT in chronic kidney disease is 30mg once daily at start and subsequent titration to 60, 90, 120 or 180 mg once daily. The dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma is 30 mg twice daily at start and subsequent titration to 60 or 90 mg twice daily, or 90mg three or four times daily as necessary to normalize serum calcium level. After oral administration of cinacalcet, maximum plasma concentration is achieved in approximately 2 to 6 hours. It has a terminal half-life of 30 to 40 hours and steady-state drug levels are reached within 7 days. Cinacalcet has a high volume of distribution (1000 L) and high protein binding (93%–97%). It is extensively metabolized in the liver, mainly by CYP3A4, CYP2D6 and CYP1A2. The primary routes of elimination are in the urine (80%) and in the feces (15%). In Phase III clinical trials involving 1136 patients with SHPT, administration of cinacalcet at 30–180 mg/day doses for 6 months produced 38–48% decrease in intact PTH. Overall, 64% of patients given cinacalcet achieved at least a 30% reduction in PTH, versus 11% of placebo patients. Calcium-phosphorous product was reduced 14% by the active treatment and did not change in the placebo group. In a much smaller clinical study involving 21 hypercalcemic patients with parathyroid carcinoma, administration of 60–360 mg/day doses of cinacalcet resulted in 71% of patients achieving a target reduction of ≥1 mg/dL in serum calcium. The most common adverse events in these trials were nausea and vomiting. In vitro, cinacalcet is a strong inhibitor of CYP2D6; therefore, dose adjustments may be required when coadministered with medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g. flecainide, vinblastine, thioridazine and most tricyclic antidepressants). Cinacalcet is prepared in a two-step synthesis starting from 3-[3-(trifluoromethyl)phenyl]propionaldehyde, by first condensing with (R)-(1-naphthyl)ethylamine to form the corresponding imine and subsequent reduction of the imine with sodium cyanoborohydride.

Chemical Properties

Off-White to Tan Solid

Originator

NPS pharmaceuticals (US)

Uses

Cinacalcet hydrochloride can be used in clinical trial in secondary hyperparathyroidism.

Uses

Cinacalcet hydrochloride is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.

Definition

ChEBI: A hydrochloride derived from equimolar amounts of cinacalcet and hydrogen chloride.

brand name

Sensipar (Amgen).

Biological Activity

Cinacalcet hydrochloride is a calcium-sensing receptor (CaSR) allosteric agonist. Activates CaSR signaling in cellular proliferation and phosphatidylinositol (PI) hydrolysis assays. Reduces serum parathyroid hormone levels in rats. Also potent CYP2D2 inhibitor (IC50 = 87 nM) and L-type calcium channel blocker. Orally bioavailable.

Mechanism of action

Cinacalcet hydrochloride directly regulates a major regulator of parathyroid hormone (PTH) secretion, the calcium-sensitive receptor (CaR) on parathyroid master cells. Cinacalcet hydrochloride reduces circulating levels of PTH by increasing the sensitivity of the CaR to extracellular calcium.

Side effects

Cinacalcet hydrochloride was generally well tolerated in clinical trials. The severity of most treatment-emergent adverse events was mild to moderate. Common side effects of Cinacalcet hydrochloride include: nausea, vomiting, or unusual tiredness. Severe may also include low calcium levels in the blood, numbness/tingling of the skin; severe muscle cramps, seizures, and abnormal heartbeat.

Synthesis

General syntheses of this class of compounds have been published, however, the specific synthesis of cinacalcet (III) has not been available to date. The synthesis of cinacalcet, based on a patented procedure, is depicted in Scheme 3. A mixture of 1-acetonaphthone (21), 3-trifluoromethyl-1-propylamine (22) and titanium (IV) isopropoxide were stirred at rt to form the enamine intermediate which was reduced with methanolic sodium cyanoborohydride at rt to give corresponding racemic a-methyl amine (23). Compound 23 was resolved and then treated with HCl etherate to give cinacalcet hydrochloride (III) as a white solid.

storage

Store at -20°C

References

[1] ureña p1, frazão jm. calcimimetic agents: review and perspectives. kidney int suppl. 2003 jun;(85):s91-6.
[2] colloton m1, shatzen e, wiemann b, starnes c, scully s, henley c, martin d.cinacalcet attenuates hypercalcemia observed in mice bearing either rice h-500 leydig cell or c26-dct colon tumors. eur j pharmacol. 2013 jul 15;712(1-3):8-15.

Cinacalcet hydrochloride(364782-34-3)Related Product Information

• 1-(1-NAPHTHYL)-2-THIOUREA
• Triethylamine hydrochloride
• Pyridine hydrochloride
• Phenylhydrazine
• CINACALCET
• 2-Ethylphenylhydrazine hydrochloride
• Ethanol
• Topotecan hydrochloride
• N-(1-(5,6,7,8-tetrahydronaphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propanamide
• Moxifloxacin hydrochloride
• Ethyl acetate
• Ethylparaben
• PHENYL VALERATE
• D-Glucosamine hydrochloride
• Parathyroid
• Bis(2-ethylhexyl)amine
• Methoxyammonium chloride
• 3-(2-TRIFLUOROMETHYL-PHENYL)-PROPIONALDEHYDE